Invasive group A streptococcal disease surveillance in Canada, 2021–2022
Alyssa Golden, Averil Griffith, Gregory J Tyrell, Julianne V. Kus, Allison McGeer, Marc-Christian Domingo, Linda Hoang, Jessica Minion, Paul Van Caeseele, Hanan Smadi, David Haldane, Yang Yu, Xiaofeng Ding, Laura Steven, Jan McFadzen, Courtney Primeau, Kristyn Franklin, Irene Martín
Abstract
Background: types, and antimicrobial resistance of iGAS isolates collected in Canada in 2021 and 2022. Methods: sequencing protocol or extracted from whole-genome sequencing data. Antimicrobial susceptibilities were determined using Kirby-Bauer disk diffusion according to Clinical and Laboratory Standards Institute guidelines or predicted from whole-genome sequencing data based on the presence of resistance determinants. Results: 12 increased from 1.0% (n=22) in 2021 to 5.8% (n=151) in 2022. These two types together accounted for almost 25% of isolates collected in late 2022 (October to December). Antimicrobial resistance rates in 2021 and 2022 included: 14.9%/14.1% erythromycin resistance, 4.8%/3.0% clindamycin resistance, and <1% chloramphenicol resistance. Conclusion: types and antimicrobial resistance patterns.